TOKYO, Apr 01 (Pulse News Wire) – Kringle Pharma,inc. (4884.T) reported the monthly exercise status of its 16th tranche warrant series, issued to EVO FUND in August 2025.
In March, 460 warrants were exercised, representing a 0.004% ratio of the total issuance of 11,500,000 warrants. As of the end of March, there were 11,495,400 unexercised warrants remaining, accounting for 99.96%. Exercise activity was concentrated on March 11 and March 12, with 130 and 330 warrants exercised respectively.
On March 11, 33,000 shares were delivered at an exercise price of ¥416 per share. Additionally, as of February 28, 2026, the outstanding share count stood at 11,500,000 (including treasury shares of 183). The company adhered to the exercise limitations set forth in Article 434 of the listing regulations, maintaining an exercise ratio within permissible limits.
🟢 Confidence: High AI-translated content.